Isis Pharmaceuticals announced that the company has earned an $18
million milestone payment from GlaxoSmithKline (GSK) related to the
advancement of the phase 2/3 study of ISIS-TTRRx in patients with
familial amyloid polyneuropathy (FAP).
"ISIS-TTRRx is the most advanced drug in our collaboration with GSK, and aside from Kynamro, it is also the furthest advanced in our late-stage clinical pipeline. We have patients who have completed fifteen months of therapy and are now receiving ISIS-TTRRx in our open-label extension study," said B. Lynne Parshall, chief operating officer at Isis. "The rapid development of ISIS-TTRRx from a research-stage programme to a drug in a late-stage clinical trial is a testament to the efficiency and productivity of our drug discovery technology platform. As this programme advances, we will continue to benefit from GSK's resources and expertise as well as earn additional milestone payments."
"ISIS-TTRRx is the most advanced drug in our collaboration with GSK, and aside from Kynamro, it is also the furthest advanced in our late-stage clinical pipeline. We have patients who have completed fifteen months of therapy and are now receiving ISIS-TTRRx in our open-label extension study," said B. Lynne Parshall, chief operating officer at Isis. "The rapid development of ISIS-TTRRx from a research-stage programme to a drug in a late-stage clinical trial is a testament to the efficiency and productivity of our drug discovery technology platform. As this programme advances, we will continue to benefit from GSK's resources and expertise as well as earn additional milestone payments."
No comments:
Post a Comment